| Literature DB >> 24489581 |
Yuwen Cen1, Ross Ka-Kit Leung2, Fuchun Zhang1, Weidong Jia1, Jiansheng Zhang1, Xinghua Tan1, Feilong Xu1.
Abstract
Objective. To determine the association between Yang-Deficient Constitution and the clinical outcomes of HIV/AIDS patients who have initiated highly active antiretroviral therapy (HAART). Method. A total of 197 antiretroviral-naive adults who initiated HAART between 2009 and 2011 were recruited. The participants were asked to complete a questionnaire twice to assess their Yang-Deficient Constitution status before HAART. During the study, signs and symptoms and CD4 or CD8 T cell counts were recorded. Routine blood and biochemical tests were conducted. For the patients who were found to have infections, pathologic examination was performed. Statistical test of association of clinical attributes and demographic factors with Yang-Deficient Constitution was conducted. Result. Good test-retest reliability was observed for Yang-Deficient Constitution scoring. The median Yang-Deficient Constitution score of 142 eligible participants was 25. Female (score = 32.14, P < 0.05), hepatotoxicity (32.14, P < 0.1), nephrotoxicity (37.50, P < 0.1), total number of adverse events (P < 0.1), and mortality (39.29, P < 0.05) were associated with Yang-Deficient Consitution, while annual changes or nadir values of CD4 or CD8 T lymphocytes, and newly acquired infections after starting HAART were not. Mortality was also associated with total number of adverse events (P < 0.05), hepatotoxicity (P < 0.05), and nephrotoxicity (P < 0.05). Conclusion. Yang-Deficient Constitution score has a potential to be developed as a predictor for early HIV-related mortality and side effects. The interrelation and underlying mechanisms should be further investigated for evidence-based design of a more appropriate treatment strategy.Entities:
Year: 2013 PMID: 24489581 PMCID: PMC3892935 DOI: 10.1155/2013/201857
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
The measuring scale for Yang-Deficient Consitution of Traditional Chinese Medicine.
| Experience/condition in the past year | Never | Sometimes | Often | Usually | Always |
|---|---|---|---|---|---|
| (1) Do you feel cold at your limbs? | 1 | 2 | 3 | 4 | 5 |
| (2) Are you sensitive to cold at stomach, back, waist, or laps? | 1 | 2 | 3 | 4 | 5 |
| (3) Are you usually sensitive to cold weather and dress more than others? | 1 | 2 | 3 | 4 | 5 |
| (4) Are you more sensitive to cold air (such as outside of winter, air-conditioning, or electric fan)? | 1 | 2 | 3 | 4 | 5 |
| (5) Do you have flu- or cold-like symptoms more frequently or easily than others? | 1 | 2 | 3 | 4 | 5 |
| (6) Do you feel uncomfortable or worried for cold water or foods? | 1 | 2 | 3 | 4 | 5 |
| (7) Do you have pulpy bowel after having cold water or foods? | 1 | 2 | 3 | 4 | 5 |
Routine blood and biochemical tests conducted and their normal range.
| Index | Normal range | Unit |
|---|---|---|
| Leukocyte | 4–10 | 10 |
| Neutrophils | 2–7.5 | 10 |
| Hemoglobin | 120–160 | g/L |
| Platelet | 100–300 | 10 |
| Seralbumin | 35–55 | g/L |
| Alkaline phosphatase | 40–150 | U/L |
| Total bilirubin | 5.1–22.2 |
|
| Aspartate transaminase | 5–40 | U/L |
| Glutamic-oxaloacetic transaminase | 5–40 | U/L |
| Glucose | 3.9–6.1 | mmol/L |
| Cholesterol | 3.1–6.0 | mmol/L |
| Low density lipoprotein cholesterol | 0–3.36 | mmol/L |
| Triglyceride | 0.79–1.70 | mmol/L |
| Sarcosine kinase | 26–174 | U/L |
| Creatinine | 44–133 |
|
| Pancreatic amylase | 22–210 | U/L |
| Lactate | 0.6–2.2 | mmol/L |
Characteristics of 142 HIV patients.
| Category | Frequency/median |
|---|---|
| Gender | |
| Male | 96 |
| Female | 46 |
| Age | 35 |
| Yang-Deficient Constitution score | 25 |
| HIV disease staging | |
| A | 57 |
| B | 16 |
| C | 69 |
| Mortality | 5 |
| CD4 count | |
| Baseline | 113 |
| 3 months after HAART | 202 |
| 6 months after HAART | 206 |
| 9 months after HAART | 229 |
| 12 months after HAART | 269 |
| CD8 count | |
| Baseline | 678.5 |
| 3 months after HAART | 837 |
| 6 months after HAART | 836 |
| 9 months after HAART | 861 |
| 12 months after HAART | 934 |
| Highly active antiretroviral therapy | |
| 3TC | 142 |
| AZT | 45 |
| D4T | 95 |
| EFV | 71 |
| NVP | 62 |
| KALETRA | 7 |
| TDF | 1 |
| Infection status before starting HAART | |
| Presence of infection before starting HAART | 50 |
| Hepatitis B | 16 |
| Hepatitis C | 19 |
| Pulmonary tuberculosis | 30 |
| Extrapulmonary tuberculosis | 12 |
| Pneumonia | 42 |
| Superficial fungal infections | 37 |
| Visceral fungal infections | 31 |
| Intestinal infections | 10 |
| Encephalitis and meningitis | 5 |
| Sexually transmitted disease | 2 |
| Newly acquired infection after HAART | |
| Presence of newly acquired infection after HAART | 29 |
| Pulmonary tuberculosis | 1 |
| Extrapulmonary tuberculosis | 6 |
| Pneumonia | 7 |
| Superficial fungal infections | 2 |
| Visceral fungal infections | 6 |
| Intestinal infections | 8 |
| Encephalitis and meningitis | 2 |
| Other infections | 5 |
| Immune reconstitution inflammatory syndrome (IRIS) | 9 |
| Adverse events | |
| Fatigue | 18 |
| Allergy | 50 |
| Alopecia | 1 |
| Gastrointestinal reaction | 44 |
| Mouth epithelium ulcer and pharyngitis | 7 |
| Cerebral symptom | 26 |
| Arthralgia | 3 |
| Diabetes | 1 |
| Hematologic toxicity | 48 |
| Hepatotoxicity | 49 |
| Abnormal lipid metabolism | 26 |
| Pancreatitis | 0 |
| Nephrotoxicity | 11 |
| Sensory nerve dysfunction | 17 |
| Hyperlactacidemia | 18 |
| Total number of side effects | 24 |
| Number of days an infection occurred after HAART initiation | 80 |
Figure 1Change of CD4 and CD8 count over a one-year period during receiving HAART. ((a), (b)) units for the scale prototypic CD4 (a) and CD8 (b) change and the number of cases assigned. ((c), (d)) Convergence was attained at about the 50th iteration for both CD4 and CD8 profile analyses.
Figure 2A hypothesis derived from the key findings about Yang-Deficient Constitution and clinical outcomes of AIDS patients. PLHIV: people living with HIV; HAART: highly active antiretroviral therapy.
(a)
| Absolute raw score difference | Frequency | ||||||
|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | |
| 0 | 115 | 105 | 118 | 100 | 107 | 116 | 107 |
| 1 | 32 | 38 | 20 | 37 | 39 | 27 | 38 |
| 2 | 9 | 15 | 14 | 17 | 10 | 11 | 11 |
| 3 | 2 | 6 | 2 | 2 | 3 | 2 | |
| 4 | 2 | 1 | |||||
(b)
| Total absolute raw score difference | Frequency |
|---|---|
| 0 | 61 |
| 1 | 11 |
| 2 | 14 |
| 3 | 11 |
| 4 | 12 |
| 5 | 15 |
| 6 | 12 |
| 7 | 7 |
| 8 | 6 |
| 9 | 1 |
| 10 | 2 |
| 11 | 3 |
| 13 | 2 |
| 16 | 1 |
(a)
| Variable | Category | Number/IQR | Correlation coefficient | Yang deficiency median score |
|
|---|---|---|---|---|---|
| Gender | Male | 96 | N/A | 22.32 | <0.05 |
| Female | 46 | 32.14 | |||
| Hepatotoxicity | Yes | 4 9 | N/A | 32.14 | <0.1 |
| No | 93 | 25.00 | |||
| Nephrotoxicity | Yes | 11 | N/A | 37.50 | <0.1 |
| No | 131 | 25.00 | |||
| HIV disease staging | A | 57 | N/A | 23.21 | <0.05 |
| B | 16 | 34.82 | |||
| C | 69 | 25.00 | |||
| Mortality | Yes | 137 | N/A | 39.29 | <0.05 |
| No | 5 | 25.00 | |||
| Age | N/A | 29–41 | −0.028 | ND | 0.74 |
| CD4 | Annual change | 77–217 | −0.028 | ND | 0.75 |
| Nadir value | 19–194 | −0.053 | ND | 0.53 | |
| CD8 | Annual change | −138–510 | −0.028 | ND | 0.74 |
| Nadir value | 334–737 | −0.13 | ND | 0.12 | |
| Total number of adverse events | N/A | 1–5 | 0.16 | ND | <0.1 |
*Wilcoxon rank sum test with continuity correction, Spearman's rank correlation, and Kruskal-Wallis rank sum test were performed where appropriate.
(b)
| Variable | Alive | Dead |
| OR | OR 95% CI | |
|---|---|---|---|---|---|---|
| Previous pneumonia | No | 99 | 1 | <0.05 | 10.42 | 1.48, 207.38 |
| Yes | 38 | 4 | ||||
| Intestinal infections | No | 131 | 3 | <0.05 | 14.55 | 1.69, 106.00 |
| Yes | 6 | 2 | ||||
| IRIS | No | 130 | 3 | <0.05 | 12.38 | 1.46, 87.72 |
| Yes | 7 | 2 | ||||
| Total number of newly acquired infections after HAART | N/A | N/A | N/A | <0.05 | 1.63 | 1.20, 2.41 |
| Hepatotoxicity | No | 92 | 1 | <0.05 | 8.18 | 1.17, 162.48 |
| Yes | 45 | 4 | ||||
| Nephrotoxicity | No | 129 | 2 | <0.05 | 24.19 | 3.55, 205.36 |
| Yes | 8 | 3 | ||||
| Total number of adverse events | N/A | N/A | N/A | <0.05 | 7.85 | 1.35, 149.63 |